ライフサイエンスコーパス: subarachnoid haemorrhage

1 mmon in poor-grade patients after aneurysmal subarachnoid haemorrhage.

2 antiplatelet therapy or in the setting of a subarachnoid haemorrhage.

3 is also a prominent feature of experimental subarachnoid haemorrhage.

4 ort-term outcome in patients with aneurysmal subarachnoid haemorrhage.

5 neurological injury from trauma, stroke and subarachnoid haemorrhage.

6 ible exception of magnesium for treatment of subarachnoid haemorrhage.

7 physiology of migraine, cluster headache and subarachnoid haemorrhage.

8 tion, primary intracerebral haemorrhage, and subarachnoid haemorrhage.

9 emorrhage, and 1.58 million (1.32-1.91) were subarachnoid haemorrhage.

10 intracranial haemorrhage, and 521 (22%) with subarachnoid haemorrhage.

11 (ROCK) and is approved for the treatment of subarachnoid haemorrhage.

12 rket than patients with ischaemic stroke and subarachnoid haemorrhage.

13 minal aortic aneurysm (0.46 [0.35-0.59]) and subarachnoid haemorrhage (0.48 [0.26-0.89]), and not ass

14 ominal aortic aneurysm (0.46, 0.35-0.59) and subarachnoid haemorrhage (0.48, 0.26-0.89).

15 47, 0.27-0.83, p=0.01) but was unchanged for subarachnoid haemorrhage (0.83, 0.44-1.57, p=0.57).

16 hage (hazard ratio 1.44 [95% CI 1.32-1.58]), subarachnoid haemorrhage (1.43 [1.25-1.63]), and stable

17 -16], intracerebral haemorrhage 28% [26-29], subarachnoid haemorrhage 16% [12-20], unspecified stroke

18 -42], intracerebral haemorrhage 44% [42-46], subarachnoid haemorrhage 22% [18-27], unspecified stroke

19 rebral vasospasm in patients with aneurysmal subarachnoid haemorrhage; (4) the use in the biomechanic

20 Subarachnoid haemorrhage, a particularly deadly form of

21 t plays important roles in migraine, stroke, subarachnoid haemorrhage and brain injury.

22 cation for many patients who have aneurysmal subarachnoid haemorrhage and can lead to delayed ischaem

23 hort have reported on the risks of recurrent subarachnoid haemorrhage and death or dependency for a m

24 with confirmatory evidence of an aneurysmal subarachnoid haemorrhage and presenting less than 96 h f

25 between the incidence of ischaemic stroke or subarachnoid haemorrhage and temperature.

26 of global as opposed to focal deficits after subarachnoid haemorrhage and traumatic brain injury in h

27 ntracranial pathologies (such as meningitis, subarachnoid haemorrhage and tumour) have been considere

28 trokes, 3% of strokes in young adults, 9% of subarachnoid haemorrhages and, of all primary intracereb

29 aemic stroke, intracerebral haemorrhage, and subarachnoid haemorrhage), and across 33 provincial admi

30 ere intracerebral haemorrhage, 702 (2%) were subarachnoid haemorrhage, and 1002 (2%) were an unspecif

31 traumatic brain injury, 139 with aneurysmal subarachnoid haemorrhage, and 151 with intracerebral hae

32 52% for rural areas and 32% for urban areas) subarachnoid haemorrhage, and 24% (22-27) for unspecifie

33 ars or older with hypertension, a history of subarachnoid haemorrhage, and a giant-sized (>20 mm) pos

34 schaemia (DCI) which occurs after aneurysmal subarachnoid haemorrhage, and often leads to cerebral in

35 ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, and unspecified type).

36 redictors were age, hypertension, history of subarachnoid haemorrhage, aneurysm size, aneurysm locati

37 pants in six prospective cohort studies with subarachnoid haemorrhage as outcome.

38 egree relative affected (FDRA) by aneurysmal subarachnoid haemorrhage (aSAH) are at a higher lifetime

39 Aneurysmal subarachnoid haemorrhage (aSAH) presents a challenge to

40 s, the outcomes for patients with aneurysmal subarachnoid haemorrhage (aSAH) remain poor, with high r

41 After aneurysmal subarachnoid haemorrhage (aSAH), extracellular haemoglob

42 erebral vasospasm (cVSP) in human aneurysmal subarachnoid haemorrhage (aSAH).

43 cal clipping or endovascular coiling after a subarachnoid haemorrhage, assuming treatment equipoise,

44 Patients with subarachnoid haemorrhage benefit from multidisciplinary

45 y (ALI) occurs in up to 30% of patients with subarachnoid haemorrhage but the incidence of ALI after

46 e complex treatment strategies applied after subarachnoid haemorrhage call for interdisciplinary coll

47 nts with ischaemic and haemorrhagic strokes, subarachnoid haemorrhage, cerebrovascular malformations,

48 ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, community-acquired bacterial m

49 emorrhage constituted 28.8% (28.3-28.8), and subarachnoid haemorrhage constituted 5.8% (5.7-6.0) of i

50 the form of cerebral microbleeds, convexity subarachnoid haemorrhage, cortical superficial siderosis

51 INTRODUCTION: Acute non-traumatic convexity subarachnoid haemorrhage (cSAH) is increasingly recognis

52 The management of patients with aneurysmal subarachnoid haemorrhage demands expertise to anticipate

53 The prognosis of subarachnoid haemorrhage depends on the severity of the

54 ulopathy, central hypoventilation, recurrent subarachnoid haemorrhage, depression, seizures and perio

55 e intensive care management of patients with subarachnoid haemorrhage, emphasizing the detection and

56 aemic stroke, intracerebral haemorrhage, and subarachnoid haemorrhage, for 204 countries and territor

57 d was diagnosed with a Hunt and Hess grade 3 subarachnoid haemorrhage from a ruptured aneurysm.

58 survivors in the Genetics and Observational Subarachnoid Haemorrhage (GOSH) Study, a retrospective m

59 linked to a greater increase in the risk of subarachnoid haemorrhage (HR 1.92, 95% CI 1.25-2.95).

60 how that axonal injury also occurs following subarachnoid haemorrhage in an animal model.

61 Here we studied acute sequelae of subarachnoid haemorrhage in the gyrencephalic brain of p

62 sk of developing intracranial aneurysms, and subarachnoid haemorrhage is a major cause of death and d

63 Aneurysmal subarachnoid haemorrhage is a potentially devastating di

64 Subarachnoid haemorrhage is often followed by haemolysis

65 of statins in patients with acute aneurysmal subarachnoid haemorrhage is unclear.

66 33 patients had a recurrent subarachnoid haemorrhage more than 1 year after their in

67 tudy (cardiac arrest, pneumonia, sepsis, and subarachnoid haemorrhage), none were deemed treatment re

68 omorbid dementia, intracerebral haemorrhage, subarachnoid haemorrhage, oesophageal varices, liver fib

69 atment (one retroperitoneal haemorrhage, one subarachnoid haemorrhage, one respiratory distress, and

70 as those with a family history of aneurysmal subarachnoid haemorrhage or unruptured intracranial aneu

71 troke (including intracranial haemorrhage or subarachnoid haemorrhage) or traumatic brain injury.

72 nit after traumatic brain injury, aneurysmal subarachnoid haemorrhage, or intracerebral haemorrhage w

73 can present with headache, ischaemic stroke, subarachnoid haemorrhage, or symptoms associated with ma

74 ved with vasoactive cerebrospinal fluid from subarachnoid haemorrhage patients.

75 Focal brain damage after aneurysmal subarachnoid haemorrhage predominantly results from intr

76 s also a functionally significant feature of subarachnoid haemorrhage, raising the prospect of common

77 ns can be rapid in patients with spontaneous subarachnoid haemorrhage (SAH) and often lead to poor cl

78 asymptomatic UIA and the risk of subsequent subarachnoid haemorrhage (SAH) by follow-up on intensive

79 etylsalicylic acid (ASA) use and spontaneous subarachnoid haemorrhage (SAH) in the general population

80 anned admission the woman was diagnosed with subarachnoid haemorrhage (SAH) in the region of the prev

81 The incidence of subarachnoid haemorrhage (SAH) is 6-8 per 100 000 person

82 Subarachnoid haemorrhage (SAH) is a type of hemorrhagic

83 Subarachnoid haemorrhage (SAH) is the third most common

84 Relatives of people with aneurysmal subarachnoid haemorrhage (SAH) may be at increased risk

85 mography angiography (CTA) is in spontaneous subarachnoid haemorrhage (SAH) patients after negative i

86 Patients with aneurysmal subarachnoid haemorrhage (SAH) secondary to ruptured ant

87 Clinical and radiological intensity of subarachnoid haemorrhage (SAH) was evaluated by using th

88 To improve outcome prediction following subarachnoid haemorrhage (SAH), we sought a biomarker in

89 mining clinical and cognitive outcomes after subarachnoid haemorrhage (SAH).

90 aemic), transient ischaemic attack (TIA) and subarachnoid haemorrhage (SAH).

91 rial hypertension (HTN) is a risk factor for subarachnoid haemorrhage (SAH).

92 ogical deterioration occurs frequently after subarachnoid haemorrhage (SAH).

93 people with no personal or family history of subarachnoid haemorrhage should be left untreated.

94 ety concerns, we conclude that patients with subarachnoid haemorrhage should not be treated routinely

95 agnosed ischaemic or haemorrhagic (excluding subarachnoid haemorrhage) stroke 5-42 days before random

96 Prognosis seems worse in patients with subarachnoid haemorrhage than in those without.

97 With the exception of subarachnoid haemorrhage, there is little evidence of se

98 Most patients with subarachnoid haemorrhage undergo surgical or endovascula

99 TCH might be the first sign of subarachnoid haemorrhage, unruptured intracranial aneury

100 human brain injured by trauma or aneurysmal subarachnoid haemorrhage, we used DC electrode recording

101 acerebral haemorrhage, and 52% of those with subarachnoid haemorrhage) went on sick leave within thre

102 ipation, while prevalences for patients with subarachnoid haemorrhage were similar in magnitude to th

103 s for patients who did not have a history of subarachnoid haemorrhage with aneurysms located in inter

104 ated ipsilateral basal ganglia bleeding with subarachnoid haemorrhage with no aetiology is uncommon.

105 ospective series of patients with aneurysmal subarachnoid haemorrhage with strong temporal correspond